NTRP:OTCQB-Neurotrope Inc (USD)

COMMON STOCK | Travel Services | OTCQB - U.S. Registered

Last Closing

USD 2.04

Change

+0.07 (+3.55)%

Market Cap

USD 0.14B

Volume

4.90K

Analyst Target

USD 1.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Neurotrope Inc is a development stage company. The Company is a clinical stage biopharmaceutical and diagnostics company, engaged in developing drug candidate called bryostatin and a diagnostic test for Alzheimer's Disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-03 )

Largest Industry Peers for Travel Services

Symbol Name Price(Change) Market Cap
BKNG Booking Holdings Inc

+13.26 (+0.34%)

USD 132.87B
ABNB Airbnb Inc

-0.23 (-0.15%)

USD 96.96B
TCOM Trip.com Group Ltd ADR

+0.10 (+0.20%)

USD 31.23B
EXPE Expedia Group Inc.

-0.64 (-0.52%)

USD 16.69B
MMYT MakeMyTrip Limited

-2.83 (-3.19%)

USD 9.39B
TRIP TripAdvisor Inc

+0.02 (+0.11%)

USD 2.48B
LIND Lindblad Expeditions Holdings ..

-0.17 (-1.81%)

USD 0.52B
TOUR Tuniu Corp

-0.02 (-2.44%)

USD 0.10B
YTRA Yatra Online Inc

N/A

USD 0.08B
ISPO Inspirato Inc

-0.09 (-2.45%)

USD 0.01B

ETFs Containing NTRP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Travel Services) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -72.73% 13% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.73% 13% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -2.23% 25% F 39% F
Dividend Return -2.23% 25% F 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.82% 100% F 73% C
Risk Adjusted Return -9.79% 25% F 35% F
Market Capitalization 0.14B N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative earnings

The company had negative total earnings in the most recent four quarters.